PortalPublikationenPhotodynamic therapy for cholangiocarcinoma using low dose m...

Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®))

Standard

Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®)). / Kniebühler, Gesa; Pongratz, Thomas; Betz, Christian S; Göke, Burkhard; Sroka, Ronald; Stepp, Herbert; Schirra, Jörg.

in: PHOTODIAGN PHOTODYN, Jahrgang 10, Nr. 3, 09.2013, S. 220-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kniebühler, G, Pongratz, T, Betz, CS, Göke, B, Sroka, R, Stepp, H & Schirra, J 2013, 'Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®))', PHOTODIAGN PHOTODYN, Jg. 10, Nr. 3, S. 220-8. https://doi.org/10.1016/j.pdpdt.2012.12.005

APA

Kniebühler, G., Pongratz, T., Betz, C. S., Göke, B., Sroka, R., Stepp, H., & Schirra, J. (2013). Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®)). PHOTODIAGN PHOTODYN, 10(3), 220-8. https://doi.org/10.1016/j.pdpdt.2012.12.005

Vancouver

Kniebühler G, Pongratz T, Betz CS, Göke B, Sroka R, Stepp H et al. Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®)). PHOTODIAGN PHOTODYN. 2013 Sep;10(3):220-8. https://doi.org/10.1016/j.pdpdt.2012.12.005

Bibtex

@article{40c1f8b0bf104d71a461b858a398b9d4,
title = "Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan({\textregistered}))",
abstract = "BACKGROUND: Photodynamic therapy (PDT) combined with stenting is an effective treatment modality for palliation of nonresectable cholangiocarcinoma (CC). A drawback of standard PDT using Photofrin({\textregistered}) as photosensitizer is the long lasting skin photosensitivity of up to 3 months. The aim of this study was to show the outcome of PDT of CC, potential side effects and to determine the best drug light interval (DLI) using mTHPC (Foscan({\textregistered})) at a low dose.METHODS: 13 patients with nonresectable CC were treated with stenting and PDT (3mg Foscan({\textregistered}) per treatment, 0.032-0.063 mg/kg body weight, 652 nm, 50 J/cm). Fluorescence measurements were performed with a single bare fiber for 5/13 patients prior to PDT at the tumor site to determine the fluorescence contrast. For another 7/13 patients, long-term fluorescence-kinetics were measured on the oral mucosa to determine the time of maximal relative fluorescence intensity.RESULTS: The results so far indicate a median survival time of 13 months. Side effects such as perforations or skin phototoxicity could not be observed. Foscan({\textregistered}) fluorescence within the tumor site was clearly detectable but a significant fluorescence contrast of tumor to adjacent healthy tissue could not be found. The fluorescence kinetics measured in the oral mucosa showed a maximum at 3.85 days (median) after drug administration.CONCLUSION: Combined stenting and PDT performed with a low Foscan({\textregistered}) dose results in equal and potentially longer survival times compared to standard Photofrin({\textregistered}) PDT, while lowering the risk of side effects strongly. Thus it may improve the quality of life.",
keywords = "Aged, Aged, 80 and over, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Cholangiocarcinoma, Dose-Response Relationship, Drug, Female, Humans, Male, Mesoporphyrins, Middle Aged, Photochemotherapy, Photosensitizing Agents, Stents, Survival Rate, Treatment Outcome, Clinical Trial, Journal Article",
author = "Gesa Knieb{\"u}hler and Thomas Pongratz and Betz, {Christian S} and Burkhard G{\"o}ke and Ronald Sroka and Herbert Stepp and J{\"o}rg Schirra",
note = "Copyright {\textcopyright} 2013 Elsevier B.V. All rights reserved.",
year = "2013",
month = sep,
doi = "10.1016/j.pdpdt.2012.12.005",
language = "English",
volume = "10",
pages = "220--8",
journal = "PHOTODIAGN PHOTODYN",
issn = "1572-1000",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®))

AU - Kniebühler, Gesa

AU - Pongratz, Thomas

AU - Betz, Christian S

AU - Göke, Burkhard

AU - Sroka, Ronald

AU - Stepp, Herbert

AU - Schirra, Jörg

N1 - Copyright © 2013 Elsevier B.V. All rights reserved.

PY - 2013/9

Y1 - 2013/9

N2 - BACKGROUND: Photodynamic therapy (PDT) combined with stenting is an effective treatment modality for palliation of nonresectable cholangiocarcinoma (CC). A drawback of standard PDT using Photofrin(®) as photosensitizer is the long lasting skin photosensitivity of up to 3 months. The aim of this study was to show the outcome of PDT of CC, potential side effects and to determine the best drug light interval (DLI) using mTHPC (Foscan(®)) at a low dose.METHODS: 13 patients with nonresectable CC were treated with stenting and PDT (3mg Foscan(®) per treatment, 0.032-0.063 mg/kg body weight, 652 nm, 50 J/cm). Fluorescence measurements were performed with a single bare fiber for 5/13 patients prior to PDT at the tumor site to determine the fluorescence contrast. For another 7/13 patients, long-term fluorescence-kinetics were measured on the oral mucosa to determine the time of maximal relative fluorescence intensity.RESULTS: The results so far indicate a median survival time of 13 months. Side effects such as perforations or skin phototoxicity could not be observed. Foscan(®) fluorescence within the tumor site was clearly detectable but a significant fluorescence contrast of tumor to adjacent healthy tissue could not be found. The fluorescence kinetics measured in the oral mucosa showed a maximum at 3.85 days (median) after drug administration.CONCLUSION: Combined stenting and PDT performed with a low Foscan(®) dose results in equal and potentially longer survival times compared to standard Photofrin(®) PDT, while lowering the risk of side effects strongly. Thus it may improve the quality of life.

AB - BACKGROUND: Photodynamic therapy (PDT) combined with stenting is an effective treatment modality for palliation of nonresectable cholangiocarcinoma (CC). A drawback of standard PDT using Photofrin(®) as photosensitizer is the long lasting skin photosensitivity of up to 3 months. The aim of this study was to show the outcome of PDT of CC, potential side effects and to determine the best drug light interval (DLI) using mTHPC (Foscan(®)) at a low dose.METHODS: 13 patients with nonresectable CC were treated with stenting and PDT (3mg Foscan(®) per treatment, 0.032-0.063 mg/kg body weight, 652 nm, 50 J/cm). Fluorescence measurements were performed with a single bare fiber for 5/13 patients prior to PDT at the tumor site to determine the fluorescence contrast. For another 7/13 patients, long-term fluorescence-kinetics were measured on the oral mucosa to determine the time of maximal relative fluorescence intensity.RESULTS: The results so far indicate a median survival time of 13 months. Side effects such as perforations or skin phototoxicity could not be observed. Foscan(®) fluorescence within the tumor site was clearly detectable but a significant fluorescence contrast of tumor to adjacent healthy tissue could not be found. The fluorescence kinetics measured in the oral mucosa showed a maximum at 3.85 days (median) after drug administration.CONCLUSION: Combined stenting and PDT performed with a low Foscan(®) dose results in equal and potentially longer survival times compared to standard Photofrin(®) PDT, while lowering the risk of side effects strongly. Thus it may improve the quality of life.

KW - Aged

KW - Aged, 80 and over

KW - Bile Duct Neoplasms

KW - Bile Ducts, Intrahepatic

KW - Cholangiocarcinoma

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Male

KW - Mesoporphyrins

KW - Middle Aged

KW - Photochemotherapy

KW - Photosensitizing Agents

KW - Stents

KW - Survival Rate

KW - Treatment Outcome

KW - Clinical Trial

KW - Journal Article

U2 - 10.1016/j.pdpdt.2012.12.005

DO - 10.1016/j.pdpdt.2012.12.005

M3 - SCORING: Journal article

C2 - 23993847

VL - 10

SP - 220

EP - 228

JO - PHOTODIAGN PHOTODYN

JF - PHOTODIAGN PHOTODYN

SN - 1572-1000

IS - 3

ER -